Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

DAIICHI S : Notice on Details of the Share Options

07/12/2011 | 04:20am US/Eastern
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126 on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)


Date of Board of Directors resolution: June 27, 2011

React to this article
17h ago RANBAXY LABORATORIES : Us court refuses ranbaxy appeal to block anda nod
1d ago AstraZeneca, Ranbaxy fail to end US trial
1d ago RANBAXY LABORATORIES : D.C. Federal Court Refuses Ranbaxy's Appeal To Block ANDA..
1d ago DAIICHI SANKYO : Luitpold Pharmaceuticals Assigned Patent
2d ago DAIICHI SANKYO : Studies from Daiichi Sankyo in the Area of Atrial Fibrillation ..
2d ago ONCOSEC MEDICAL : and Plexxikon Collaborate to Explore Combination Immunotherapy..
2d ago DAIICHI SANKYO : Social Media Use in the Sales & Marketing of Prescription Drugs..
3d ago Indians line up in US for blowing whistles
3d ago Us overturns ranbaxy bid to block launch of nexium, valcyte generics
4d ago RANBAXY LABORATORIES : Whistle-blowing from india up four-fold, says us sec repo..
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes